Ghrelinomimetic

Ghrelinomimetics, also called growth hormone secretagogues (GHS), are synthetic compounds that activate the growth hormone secretagogue receptor type 1a (GHSR-1a), a seven-transmembrane G-protein-coupled receptor whose endogenous ligand is ghrelin, a 28-amino-acid acylated peptide produced primarily by gastric X/A-like cells. Upon binding, GHSR-1a preferentially couples to Gαq/11 proteins, triggering the phospholipase C (PLC)/inositol trisphosphate (IP3) cascade and releasing calcium from intracellular stores. The resulting elevation in cytosolic calcium drives exocytosis of secretory granules from pituitary somatotrophs, producing pulsatile growth hormone (GH) release.

At the hypothalamic level, GHS compounds activate neuropeptide Y and agouti-related peptide co-expressing neurons in the arcuate nucleus, amplifying GH pulse amplitude. Simultaneous activation of GHSR-1a at both sites produces a GH secretory response that is synergistic with GHRH acting at its own distinct pituitary receptor.

Beyond the GH axis, GHSR-1a engages multiple downstream pathways: MAPK/ERK1/2 (cell proliferation and differentiation), PI3K/AKT (glucose metabolism and cell survival), AMPK (peripheral energy homeostasis), and mTOR/S6K1 (appetite and protein synthesis). Anti-inflammatory actions involve suppression of p38 MAPK, JNK, and p65 NF-κB phosphorylation, with concurrent reductions in TNF-α and IL-6 that contribute to tissue-healing and cardioprotective effects observed in preclinical models. GHSR-1a also exhibits constitutive activity independent of ligand binding, mediated by aromatic clusters in transmembrane domains VI and VII.

The most rigorous human evidence comes from the anamorelin ROMANA trials and multiple randomized studies of MK-677 (ibutamoren), an oral non-peptide ghrelin mimetic.

Chapman et al. (1996, PMID 8954023) enrolled 32 healthy elderly subjects (ages 64-81) in a double-blind, placebo-controlled study. Oral MK-677 25 mg daily for 28 days increased mean 24-hour GH concentration by 97% and restored serum IGF-1 from 141 to 265 mcg/L, reaching young-adult reference ranges. Nass et al. (2008, Annals of Internal Medicine, n=65, ages 60-81) conducted a 2-year double-blind modified crossover trial. MK-677 increased fat-free mass by 1.1 kg versus a decline of 0.5 kg with placebo over 12 months, though functional strength measures were not significantly improved. Fasting glucose rose by approximately 0.28 mmol/L and insulin sensitivity declined. A phase IIb trial of MK-677 (Adunsky et al. 2011, Archives of Gerontology and Geriatrics, DOI 10.1016/j.archger.2010.10.004, n=123 elderly hip fracture patients) was halted early after a numerically higher rate of congestive heart failure in the treatment arm (6.5% vs 1.7% placebo), preventing definitive efficacy conclusions.

For anamorelin, the ROMANA 1 (n=484) and ROMANA 2 (n=495) phase 3 randomized, double-blind trials tested 100 mg once daily in inoperable stage III-IV non-small-cell lung cancer with cachexia. Both trials showed statistically significant lean body mass gains versus placebo (ROMANA 1: +0.99 kg vs -0.47 kg; ROMANA 2: +0.65 kg vs -0.98 kg; both p less than 0.0001), but neither met the co-primary endpoint of improved hand grip strength (p=0.15 and p=0.65). The ROMANA 3 safety extension (n=513, 12 additional weeks) confirmed acceptable tolerability with no new safety signals. Anamorelin received regulatory approval in Japan in December 2020 for cachexia in four cancer types but was not approved by the FDA due to the handgrip strength failure.

For ipamorelin, a proof-of-concept randomized controlled trial (Beck et al. 2014, n=87) found intravenous ipamorelin 0.03 mg/kg twice daily well tolerated in bowel resection patients with postoperative ileus, though the study was underpowered for functional endpoints. Preclinical evidence for GHS compounds in tissue healing includes a rat model of combined radiation-burn injury (Liu et al. 2016, PMID 27271793) in which ghrelin treatment (200 nmol/kg) accelerated wound closure by 3-8 days and reduced TNF-α by up to 54% through GHS-R1a-mediated NF-κB suppression. Controlled human wound-healing data for peptide GHRPs (GHRP-2, GHRP-6, hexarelin) are not available; evidence for these compounds in humans is limited to small acute GH secretion studies.

Typical dosage: 100-200 mcg (daily).

Dosages below reflect published clinical trial parameters and, for compounds lacking regulatory approval, research protocols documented in the peer-reviewed literature and clinical compounding practice. Actual dosing for any patient should be individualized by a licensed clinician.

MK-677 (ibutamoren, oral non-peptide): Phase 2 and phase 3 trials used 25 mg once daily by mouth. Some investigators initiated at 10 mg daily for 2-4 weeks before titrating to 25 mg for tolerability. The plasma half-life of approximately 24 hours supports once-daily dosing. Published trial durations range from 14 days to 2 years. Doses above 25 mg have not been evaluated in controlled trials.

Anamorelin (oral non-peptide, Japan-approved): 100 mg once daily on an empty stomach. Discontinuation is recommended if no clinical benefit is observed within 3 weeks. The ROMANA extension trial accumulated 24 weeks of safety data.

Ipamorelin (synthetic pentapeptide, subcutaneous): Research protocols describe 200-300 mcg subcutaneously 2-3 times daily, administered in a fasted state to minimize interference from somatostatin-mediated GH suppression. Its hormonal selectivity (absence of meaningful cortisol or prolactin elevation) permits higher-frequency dosing relative to less selective GHRPs.

GHRP-2 (synthetic hexapeptide, subcutaneous): 100-300 mcg subcutaneously 1-3 times daily. Community research protocols frequently employ intermittent schedules (e.g., 5 days on, 2 days off) to limit receptor desensitization. Fasted administration is standard.

GHRP-6 (synthetic hexapeptide, subcutaneous): 100-150 mcg subcutaneously 2-3 times daily, on an empty stomach. Notably stimulates appetite.

Hexarelin (synthetic hexapeptide, subcutaneous): 50-100 mcg subcutaneously once daily. Rapid receptor desensitization with continuous use is well documented; cyclical use is commonly described in research contexts.

This content is provided for educational and reference purposes only and does not constitute medical advice. Appropriate dosing, indications, and monitoring for any growth hormone secretagogue must be determined by a qualified healthcare professional.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The pharmacologically best-supported combination strategy involves pairing a ghrelinomimetic with a GHRH analog such as CJC-1295 (modified GRF 1-29, with or without a drug-affinity complex). GHRH-receptor activation increases the pool of somatotrophs primed for GH release while GHSR-1a stimulation provides the triggering signal; because these receptors are distinct, co-activation produces GH pulses substantially larger than either agent alone, a synergy documented in pharmacodynamic studies. Ipamorelin is most frequently paired with CJC-1295 in clinical compounding practice because its selective hormonal profile (minimal cortisol, ACTH, or prolactin elevation) limits additive endocrine side effects. No published human randomized controlled trials have formally evaluated any GHRH-plus-GHRP combination protocol against clinical endpoints such as lean mass gain, fracture healing, or functional recovery.

GHRP-2 or GHRP-6 are also combined with GHRH analogs in community research settings, though their cortisol and prolactin-stimulating properties (more pronounced with GHRP-6 and hexarelin) make them less favored for extended co-administration. Sermorelin plus ipamorelin is reported in some clinical compounding contexts as an alternative to the CJC-1295 pairing. Stacking multiple GHRPs simultaneously is anecdotally reported in fitness communities but lacks any controlled evidence and is not recommended practice.

Ghrelinomimetic is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Increased hunger, water retention

Metabolic effects represent the predominant safety concern across the class. All well-studied ghrelinomimetics cause dose-dependent increases in fasting blood glucose and reductions in insulin sensitivity through GH-driven gluconeogenesis and lipolysis. In the MK-677 trials, fasting glucose rose by approximately 0.28-0.50 mmol/L compared to placebo. Impaired fasting glucose or pre-existing diabetes mellitus constitutes a contraindication to GHS use or requires careful glycemic monitoring.

Fluid retention and peripheral edema are common, particularly with MK-677, reflecting sodium-retaining properties of elevated GH. Increased appetite is prominent with GHRP-6 and to a lesser degree with other class members. Carpal tunnel-like sensations and joint discomfort consistent with GH-related interstitial fluid shifts have been reported.

The Adunsky et al. 2011 phase IIb trial in 123 elderly hip fracture patients identified a numerically higher rate of congestive heart failure in the MK-677 arm (6.5% vs 1.7% placebo), leading to early trial termination. This signal is thought to involve GH-induced fluid retention in patients with subclinical cardiac vulnerability and argues for caution in elderly patients with cardiac history.

Sustained IGF-1 elevation raises a theoretical concern for promotion of mitogenic activity, given IGF-1's established role in cell proliferation; however, the anamorelin NSCLC trials did not detect an oncology signal over 24 weeks. Long-term IGF-1 consequences in healthy adults receiving GHS are not well characterized.

For peptide GHRPs specifically: GHRP-2, GHRP-6, and hexarelin stimulate cortisol and ACTH release in a dose-dependent manner; hexarelin produces the greatest HPA axis activation and undergoes faster receptor desensitization with continuous dosing. Ipamorelin does not release ACTH or cortisol at levels differing from GHRH even at doses exceeding 200-fold the GH-releasing ED50, making it the most endocrinologically selective compound in this class. Injection-site erythema and bruising are common with subcutaneous peptide administration. Anamorelin is contraindicated in pregnancy and in patients with known hypersensitivity; hyperglycemia was the most common drug-related adverse event in its ROMANA trials (1.2% active vs 0.0% placebo).